To be resubmitted is the BLA for the steroid-refractory acute graft against host disease candidate.

Published Date: 06 Jun 2024

Remestemcel-L's BLA resubmission is anticipated to be submitted to the FDA this quarter, according to Mesoblast Limited's CEO.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot